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T cell receptor (TCR) binding to diverse peptide-
major histocompatibility complex (pMHC) ligands
results in various degrees of T cell activation. Here
we analyze which binding properties of the TCR-
pMHC interaction are responsible for this variation
in pMHC activation potency. We have analyzed acti-
vation of the 1G4 cytotoxic T lymphocyte clone by
cognate pMHC variants and performed thorough
correlation analysis of T cell activation with 1G4
TCR-pMHC binding properties measured in solution.
We found that both the on rate (kon) and off rate (koff)
contribute to activation potency. Based on our
results, we propose a model in which rapid TCR
rebinding to the same pMHC after chemical dissoci-
ation increases the effective half-life or ‘‘confinement
time’’ of a TCR-pMHC interaction. This confinement
time model clarifies the role of kon in T cell activation
and reconciles apparently contradictory reports on
the role of TCR-pMHC binding kinetics and affinity
in T cell activation.
INTRODUCTION
Specific activation of T cells by cognate antigen is the central
event in mounting adaptive immune responses. The specificity
of T cell activation is achieved by tightly regulated T cell receptor
(TCR) recognition of antigenic peptides in complex with major
histocompatibility complex (pMHC) glycoproteins presented by
antigen-presenting cells (APCs) or target cells (Burroughs and
van der Merwe, 2007). Any given TCR has the ability to bind to
a large number of distinct pMHCs, leading to various functional
outcomes. Depending on the engaged pMHC, T cells can be
activated (stronger or weaker agonist) or inactivated (antago-
nist), or pMHC binding can have no effect (null peptide) (Germain
and Stefanova´, 1999; Kersh and Allen, 1996). Although it is
generally accepted that the potency of pMHC depends on the
‘‘strength’’ of its binding to TCR, there is controversy over whichof the chemical parameters governing binding are the primary
determinants of successful signaling (Kersh and Allen, 1996;
van der Merwe, 2001).
The mechanism of signal transduction across the T cell mem-
brane upon binding of pMHC to TCR, a process termed TCR trig-
gering, is also controversial. There are several proposed models
that can be divided into three groups depending on whether they
invoke aggregation, conformational change, or segregation of
the TCR (Choudhuri et al., 2005; Choudhuri and van der Merwe,
2007; van der Merwe, 2001). Understanding which TCR-pMHC
binding properties determine the potency of pMHC will improve
our understanding of the molecular processes that accompany
TCR triggering and place constraints on TCR triggering models.
The ability to predict the potency of pMHC based on the TCR-
pMHC bond parameters will assist in the rational design of anti-
tumor peptide vaccines, because many tumor-specific antigens
provoke only weak immune responses that are incapable of
eliminating all tumor cells. One well-studied tumor-associated
protein is NY-ESO-1 (Chen et al., 1997), which is presently
a candidate antigen for antitumor vaccines being developed to
enhance immune responses against a variety of tumors. One
of the most immunogenic HLA-A2-restricted peptides derived
from the NY-ESO-1 protein is NY-ESO-1157-165 (ESO-9C pep-
tide) (Ja¨ger et al., 1998). However, immune responses initiated
by the peptide are still not sufficient for complete tumor elimina-
tion, possibly because of its instability (see below). The design of
NY-ESO-1157-165 altered peptide ligands (APLs) that induce
a better antitumor response could have important therapeutic
benefits (Apostolopoulos et al., 2000; Chen et al., 2005; McMa-
han et al., 2006; Webb et al., 2004).
The majority of published data supports either kinetic or
affinity models of pMHC potency. Kinetic models (Kalergis
et al., 2001; Kersh et al., 1998; McKeithan, 1995) propose that
a productive signal is transduced by the TCR provided it remains
bound to pMHC for a minimum period of time. For example, the
kinetic proofreading model postulates that a series of biochem-
ical modifications accumulate at the bound TCR that are lost
upon pMHC dissociation. A productive signal is transduced
only if the pMHC remains bound long enough to allow the TCR
to reach a critical modification. Direct and indirect support for
the model has come from studies that have shown good corre-
lation between the T cell response and the TCR-pMHC bondImmunity 32, 163–174, February 26, 2010 ª2010 Elsevier Inc. 163
0.01
0.10
1.00
9C 9L 9V 3A 3I 3M 3Y 4D 6V 6T 7H R65 H70 H74 R75 V76 K146F
ol
d 
di
ffe
re
nc
e 
co
m
pa
re
d 
to
 
E
S
O
-9
V
 - 
H
LA
-A
2
KA
t1/2
kon
Figure 1. Binding Properties of 1G4 TCR Interaction with pMHC Variants
Binding affinity and kinetics of 1G4 TCR interaction with a range of ESO-9V-HLA-A2 variants was measured at 37C by SPR (see Figure S1). Effect of peptide or
HLA-A2 amino acid substitution on 1G4 TCR binding affinity and kinetics is presented as a fold difference compared to ESO-9V-HLA-A2. Substitutions that nega-
tively affected 1G4 TCR binding have relative affinities and kinetics lower than 1. Values shown are the mean ± SEM of at least three independently performed
experiments.
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TCR-pMHC Confinement Time and T Cell Activationoff rate (koff) (Carren˜o et al., 2007; Kalergis et al., 2001; Kersh
et al., 1998; Krogsgaard et al., 2003; Qi et al., 2006). The affinity
model postulates that the total number of TCR-pMHC com-
plexes formed at equilibrium is the primary determinant of the
T cell response. In support of this model, a number of studies
reported correlations between the TCR-pMHC dissociation con-
stant (KD), but not koff, and the T cell response (Andersen et al.,
2001; Boulter et al., 2007; Holler and Kranz, 2003; McMahan
et al., 2006; Tian et al., 2007).
Many of the studies supporting the affinity and kinetic models
of pMHC potency include examples of discrepancies in the
correlations they report (al-Ramadi et al., 1995; Baker et al.,
2001; Hudrisier et al., 1998; Krogsgaard et al., 2003). Several
factors may account for these discrepancies. First, the majority
of studies were performed with small numbers of pMHC ago-
nists, limiting the reliability of observed correlations. Second,
assays of T cell activation were performed by stimulating cells
with various pMHC without always fully controlling for differ-
ences in peptide processing, loading, and stability. Third, solu-
tion binding parameters were mainly measured at 25C rather
than 37C, the relevant temperature at which functional assays
are performed. Fourth, TCR-pMHC solution binding or three-
dimensional (3D) binding properties might be different compared
to functionally relevant membrane or two-dimensional (2D)
binding properties, where both pMHC and TCR are immobilized
to surfaces. In such a constrained environment, the likelihood
of protein rebinding after chemical dissociation is greatly
enhanced, which would probably have a large impact on its 2D
koff. Finally, variations in measured TCR-pMHC bond affinity in
themajority of studies result mostly from differences in koff rather
than kon, potentially masking the importance that kon may have in
T cell activation.
In order to explore which binding properties determine pMHC
potency, we have performed a detailed study of 1G4 TCR (Chen
et al., 2005) binding to a large set of various NY-ESO157-165
altered peptide ligands in complex with either wild-type or
mutated HLA-A2. In separate experiments, we analyzed the acti-
vation of the 1G4 cytotoxic T lymphocyte (CTL) clone (fromwhich
the 1G4 TCR was isolated) by either immobilized pMHC or
peptide-pulsed APCs, precisely controlling for equal pMHC
presentation. Detailed statistical analysis reveals that models
of T cell activation based solely on KD or koff do not robustly fit
the data. However, a model based on the postulated confine-164 Immunity 32, 163–174, February 26, 2010 ª2010 Elsevier Inc.ment time of the TCR-pMHC interaction explains our data set.
The proposed model reduces to simpler models dependent
solely on KD or koff in certain limits, and therefore reconciles
observations from previous reports.
RESULTS
Analysis of Binding Properties of 1G4 TCR Interaction
with NY-ESO157-165 APLs and HLA-A2 Mutants
We first designed various NY-ESO157-165 APLs and HLA-A2
mutants that bind to 1G4 TCR with a wide range of binding char-
acteristics. It has been demonstrated that a substitution of the
highly unstable cysteine amino acid to valine (ESO-9V) or leucine
(ESO-9L) at the anchor position 165 of NY-ESO157-165 improves
loading efficacy of peptide onto HLA-A2 and its subsequent
immunogenicity (Chen et al., 2000). We produced a set of
ESO-9V APLs by substituting amino acids at the positions 3, 4,
5, 6, 7, and 8 in the peptide. In addition, we have generated
a set of HLA-A2 variants with various mutations within the 1G4
TCR binding ‘‘footprint’’ (Chen et al., 2005) (R65, H70, H74,
R75, V76, K146). The affinity, kinetics, and thermodynamics of
1G4 TCR binding to 17 pMHC variants (APLs and HLA-A2
mutants) were analyzed by SPR at 37C (Figure 1; Figure S1
and Table S1 available online).
Activation of 1G4 CTLs by Immobilized
or Cell-Presented pMHCs
pMHC immobilized to planar surfaces is often used as an alter-
native to cell-based assays for T cell activation and is a potent
inducer of many T cell functions (Gonza´lez et al., 2005; Krogs-
gaard et al., 2003). An important advantage of this assay is
that the pMHC dose is independent of peptide affinity for MHC
and can be precisely controlled. Activation of 1G4 CTLs by
pMHC variants was analyzed by measuring interferon-gamma
(IFN-g) secretion by cells stimulated by graded concentrations
of pMHCs (Figures 2A–2C). The activation potency (EC50) of
pMHCs was determined from the pMHC concentration that
stimulated half-maximal IFN-g secretion (Table S1). To control
for variation in pMHC stability and concentration, the amounts
of immobilized pMHC were measured with a conformation-
sensitive antibody (Figures S2A–S2C).
Although functional assays with plate-bound pMHC allow
precise control of the amounts of ligand, they have the
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Figure 2. Functional Response of 1G4 T Cells to pMHC Variants
(A–C) IFN-g release from 1G4 CTLs stimulated by plate-bound pMHC variants. 1G4 CTLs were cultured for 4 hr in 96-well plates coated with indicated concen-
trations of pMHC variants. Supernatants were collected and secreted IFN-gwasmeasured by ELISA. One of at least three independently performed experiments
is shown.
(D–E) Cytotoxic response of 1G4 CTLs to NY-ESO157-165 peptide variants. A 1:1 ratio of 1G4 CTLs and
51Cr-labeled T2 cells were pulsed with the indicated
peptide dilutions starting from the concentration shown in previous experiments (Figure S2D) to give a 40% increase in surface HLA-A2 expression (C40%) on
T2 cells. After 4 hr incubation at 37C, specific lysis of T2 cells was analyzed bymeasuring released 51Cr. One of at least three independent experiments is shown.
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TCR-pMHC Confinement Time and T Cell Activationdisadvantage of being unphysiological. We therefore also
investigated the stimulatory effect of ESO-9V APLs in a more
physiological, cellular context by performing a cytotoxicity
assay. As target cells we used the transporter associated with
antigen processing (TAP)-deficient T2 cell line (Cerundolo
et al., 1990) pulsed with various ESO-9V APLs, precisely match-
ing for surface pMHC expression (Figures 2D and 2E). The
relative potency (EC50) of peptides was determined from the
dilution of peptide resulting in half-maximal lysis of target cells
(Table S1).
We next explored which of the measured binding parameters
governing the TCR-pMHC interaction are the best predictors ofthe T cell response. Correlations between pMHC potency in
inducing T cell responses and 17 binding parameters (not all of
which are independent) are shown in Table 1, a subset of which
are plotted in Figure 3. We found significant correlations (R2 >
0.7, p < 0.01) only with KD (Figure 3A), koff (Figure 3B), and
parameters derived from these measurements (e.g., DG,
DGzdiss). There was a weak correlation with kon (Figure 3C) but
no correlation with enthalpy change (Figure 3D) or activation
enthalpy change of dissociation (Figure 3E), the significance
of which is discussed below. Thus we found in two different
functional assays that pMHC potency correlates with both KD
and koff.Immunity 32, 163–174, February 26, 2010 ª2010 Elsevier Inc. 165
Table 1. Correlation between pMHC Potency and TCR-pMHC
Binding Parameters
TCR/pMHC
Bond
Parametera
IFN-g Release (EC50)
b Cytotoxicity (1/log(EC50))
b
R2 p Value R2 p Value
KD 0.719 1.70E-05 0.882 1.70E-04
koff 0.776 3.04E-06 0.960 3.73E-06
t1/2 0.358 0.0111 0.652 0.0085
kon 0.320 0.0179 0.633 0.0103
1/kon 0.012 0.6735 0.709 0.0044
DG 0.624 0.0002 0.746 0.0027
DH 0.077 0.2812 0.006 0.8424
-TDS 0.001 0.9064 0.044 0.5901
DC 0.221 0.0569 0.110 0.3826
DGzdiss 0.462 0.0027 0.603 0.0138
DHzdiss 0.060 0.3443 0.108 0.3884
-TDSzdiss 0.036 0.4666 0.070 0.4921
DCzdiss 0.047 0.4055 0.058 0.5327
DGzass 0.202 0.0700 0.127 0.3469
DHzass 0.098 0.2219 0.030 0.6539
-TDSzass 0.012 0.6793 0.082 0.4544
DCzass 0.075 0.2891 0.034 0.6360
aMeasured EC50 values are correlated to various TCR-pMHC bond
parameters via data fitting in Matlab. Standard methods are used to
calculate the R2 statistic, which is the square of the correlation coefficient
for these simple models, and p values are obtained with an F-test. Details
can be found in the Supplemental Information. The quality of the fit for
several bond parameters is shown in Figure 3.
bWe use the reciprocal of EC50 for the cytotoxicity assay because it is ob-
tained from a dilution curve. We take the log to account for effects of
nonlinear loading of peptide to APCs. The use of EC50 in both assays is
discussed in the Supplemental Information.
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TCR-pMHC Confinement Time and T Cell ActivationRemoving Bias by Subset Analysis
The T cell response correlated well with both KD and koff when
examining the entire data set (Table 1, Figures 3A and 3B).
However, the correlation between KD and koff is strong (R
2 =
0.73) among the pMHC variants used in the present study (Fig-
ure 4A) as the kon varied somewhat less than the koff (Figure 1).
This made it difficult to resolve whether KD or koff determine
potency or to identify a contribution from kon. In order to investi-
gate the contribution of kon, we extracted subsets of the entire
data set (17 pMHC variants for IFN-g assay) that contain fewer
pMHC variants selected to minimize the correlation between
KD and koff and thus maximize the variation in kon. When more
than two peptides were removed, the correlation between KD
and koff rapidly approached zero (Figure 4B). Next, we fitted
both KD and koff models to these subsets (see Experimental
Procedures). Surprisingly, we found that both exhibited a poor
fit (reduced R2 value) as the correlation between KD and koff
was reduced and the variability in kon increased (Figure 4B).
This is illustrated by the poor fits of both KD and koff for the subset
of 13 pMHC variants (Figures 4C and 4D). In Table 2 we summa-
rize the fits (R2 statistic) and their significance (p value). It is
evident that once three or more pMHC variants are removed,
neither KD nor koff correlate significantly with pMHC potency
(p > 0.05).166 Immunity 32, 163–174, February 26, 2010 ª2010 Elsevier Inc.The nine APLs used in the cytotoxicity assay also exhibited
a large KD-koff correlation (R
2 = 0.89). However, it was not
possible to perform the subset analysis because of the limited
amount of data. Correlations for these nine APLs with IFN-g
release were similar to the cytotoxicity assay (not shown).
Thus, pMHC potency cannot be described by either koff or KD
for the present data set.Importance of the TCR-pMHC Bond kon in a Model
of Confinement Time
The observation that the basic KD and koff models fit poorly when
kon varies suggested that kon is an important determinant of the
T cell response, which is consistent with the weak correlation
that we observed with kon (Figure 3C). Motivated by these obser-
vations and recent experimental work (Tolentino et al., 2008),
we investigated a simple model whereby rapid rebinding of
a TCR to the same pMHCmolecule counters the effects of mem-
brane diffusion (or transport), effectively confining TCR-pMHC,
as schematically presented in Figure 5A. In this confinement
time model, we can calculate the total time the TCR will be in
complex with the same pMHC (integrated across multiple
rebinding events) as Tc = (k*on + k)/(kkoff) and the total time
the TCR will be unbound but within the reaction radius (i.e.,
binding range) of the pMHC as Tf = 1/k. In these equations,
k*on (in units of s
1) is the intrinsic localized on rate between
a single TCR-pMHC pair and is related to the solution on rate
by a multiplicative factor (see Experimental Procedures), and
k (in units of s
1) is the rate at which TCR-pMHC move (diffuse)
apart. With reasonable parameters we found that Tc > > Tf
(see Experimental Procedures), indicating that the total time
that TCR and pMHC are confined to one another is determined
by Tc. The reciprocal of Tc determines an effective off rate
(k*off) that captures the rate at which TCR and pMHC move
apart,
koff =
1
Tc
= k koff=

kon + k

:
This expression reflects the rate of unbinding and the proba-
bility of moving apart before rebinding. A full description of the
model can be found in Experimental Procedures.
In certain limits, the confinement time model reduces to the
basic models. When the intrinsic on rate is large compared to
the diffusive rate (k*on > > k), the confinement time is directly
proportional to KD (k*off = k+KD). In contrast, when k*on < < k,
the effective off rate is simply k*off = koff because TCR-pMHC
move apart without rebinding. Measurements of binding con-
stants represent intrinsic rates because experiments were per-
formed in a flow chamber (BIAcore) under conditions that mini-
mize rebinding events. In other words, dissociation in the flow
chamber leads to transport rather than localized rebinding.
In Figure 5B we showed the results of fitting the confinement
time model to the entire data set. We found an improved corre-
lation (R2 = 0.83) compared to the basic models of KD and koff.
Next, we fitted the confinement time model to the pMHC
variant subsets described in the previous section and found
that the R2 statistic remained large for all subsets (Figures 4B
and 5C for the 13 pMHC subsets). In contrast to the KD
and koff models, we found that the confinement time model
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Figure 3. Correlation between T Cell Response and TCR-pMHC Binding Properties
Correlations are shown between pMHC potency, represented by the concentration stimulating half-maximal IFN-g secretion (EC50), and (A) the TCR-pMHC bond
dissociation constant (KD), (B) the bond off rate (koff), (C) the bond on rate (kon), (D) the change in enthalpy (DH), and (E) activation enthalpy of dissociation (DH
z
diss).
Table 1 contains correlations with additional thermodynamic parameters. Significant correlations (p < 0.05) are found only for KD, koff, and kon and other param-
eters that are directly derived from these. The R2 statistic is the square of the correlation coefficient for these simple models and p values are computed with an
F-test. Both quantities are calculated in Matlab with standard methods; see Supplemental Information for details.
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TCR-pMHC Confinement Time and T Cell Activationremained significant (p < 0.05) for all except one subset of the
data (Table 2).Potential Effects of Molecular Flexibility
It has been previously proposed that the heat capacity is impor-
tant in relating the solution koff to the physiological membrane koff
because heat capacity reflects molecular flexibility, and this may
affect the dissociation rate of membrane-tethered molecules
(Krogsgaard et al., 2003; Qi et al., 2006). This molecular flexibility
model, as applied to the present data, predicts that the T cell
response will be related to koffexp(bDCp), where b is a constant
(see Experimental Procedures for details on data fitting). Shown
in Figure 5D are the results of fitting the molecular flexibility
model to the entire data set. We find a small improvement in
the R2 statistic compared to a model of koff alone (Figure 3B).
Moreover, performing the subset analysis (Figures 4B and 5E
and Table 2), we observed improved R2 values for only two
data subsets (five or seven pMHC variants removed).
The processes of molecular flexibility and confinement time
are not mutually exclusive. We therefore formulated the
combined model and performed data fitting (see Experimental
Procedures). The combined model depends on koff, kon, and
DCp and has four free parameters. In Figure 5Fweplot the results
of data fitting to this model by using the entire data set and find,
as expected, an improved fit (R2 = 0.89). Results from the subset
analysis can be seen in Figure 4B and Table 2 and are visualized
for the 13 pMHC subsets in Figures 5E and 5G for the molecular
flexibility and the combined model, respectively. Thus, themolecular flexibility model does not account for the potency of
the pMHC variants in this system.A Statistical Test for Model Comparisons Reveals
the Importance of the Confinement Time Model
It is not surprising that the confinement time (three free parame-
ters), molecular flexibility (three free parameters), and combined
models (four free parameters) exhibit improved R2 values
compared to the simple models of KD and koff (two free parame-
ters). In order to determine whether the increase in the quality
of the fit, as reported by an increase in R2, is not simply due to
an increase in the number of free parameters, we performed an
F-test for nested models. This statistical test provides a p value
for the null hypothesis that the simpler model is sufficient to
explain the data (Motulsky and Christopoulos, 2004) (see Exper-
imental Procedures). In Table 2 we report p values based on this
statistical test. A p value below 0.05 indicates that themodel with
more parameters significantly improves the fit. We found that the
confinement time model provided a statistically significant (p <
0.05) improvement in the fit compared to the simple models of
KD and koff, with the exception of three subsets. In contrast,
the molecular flexibility model significantly improved the fit
(compared to the basic koff) only for the subsets with five or seven
pMHC variants removed. The combined confinement time and
molecular flexibility model (four free parameters) was a better
descriptor of the data (p < 0.05) compared to molecular flexibility
alone but only in some instances did it significantly improve the
fit compared to the confinement time model.Immunity 32, 163–174, February 26, 2010 ª2010 Elsevier Inc. 167
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Figure 4. Analysis of Model Fitting to Data Subsets with Larger Variability in the On Rate
(A) The 17 pMHC variants that comprise the entire data set exhibit a large correlation between KD and koff (R
2 = 0.74). By systematically removing a fixed number of
pMHC variants, we identified the subset that minimized the KD-koff correlation. For example, we calculated the correlation for all 17 possible subsets of 16 pMHC
variants and selected the subset with the smallest KD-koff correlation.
(B) The square of the KD-koff correlation as a function of the number of pMHC variants removed for the subset with the smallest correlation. In this way, we gener-
ated data sets with lower KD-koff correlations and hence larger variability in the on rate. Also shown in (B) is the R
2 statistic for fits of the KD, koff, molecular flexibility
(MF), confinement time (CT), and the combined model (MF+CT) to all subsets considered. Computations for subsets consisting of less than eight pMHC variants
did not provide reliable results because the number of parameters approached the number of data points.
(C and D) The correlations of pMHC potency with KD and koff for the subset of 13 pMHC variants (i.e., when 4 pMHC variants are removed). See Figure 5 for
correlations with other models. In Table 2 we report the p values associatedwith each fit, showing that when removingmore than two pMHC variants, correlations
with KD and koff are not significant (p > 0.05). Also shown in Table 2 are p values associated with an F-test that determines whether the additional parameter(s) in
the CT, MF, and combined model is significant. The fitted parameters from each model are listed in Table S2.
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a more robust description of the data than does the molecular
flexibility model. However, a combination of the two models is
also able to improve the fit in some circumstances.
DISCUSSION
In our study we have determined the functional response of 1G4
CTLs to a panel of 17 pMHC variants consisting of APLs and
HLA-A2 mutants. With this large data set, we have found that
pMHC potency is not well correlated to either KD or koff when
examining data subsets with larger variability in kon. We found
that a model of TCR-pMHC confinement time provided consis-
tently larger correlations than did alternative models. By using
rigorous statistical analysis (an F-test for nested models), we
have shown that these improved correlations are not simply
due to the addition of extra fitting parameters.
Our study differs from previous studies in that it examines
a larger number of pMHC variants with a wide variation in kon,
enabling us to clarify the role of kon in pMHC potency. Most
previous studies are nevertheless consistent with, and therefore
support, our proposed confinement time model. For example, in
a study in which the kon varied little or much less than the koff, it168 Immunity 32, 163–174, February 26, 2010 ª2010 Elsevier Inc.was found that the pMHC potency correlates with both koff and
KD (Chervin et al., 2009). Other studies have reported a correla-
tion between pMHC potency and either KD (Andersen et al.,
2001; Boulter et al., 2007; Holler and Kranz, 2003; McMahan
et al., 2006; Tian et al., 2007) or koff (Carren˜o et al., 2007; Kalergis
et al., 2001; Kersh et al., 1998; Krogsgaard et al., 2003; Qi et al.,
2006). This apparent conflict can be reconciled because the
confinement time model reduces to the koff or KD models under
certain conditions. When there is little rebinding (kon is small),
then k*off approaches koff, whereas if rebinding is frequent (kon
is large), then k*off approaches KD. In agreement with this, in
studies where TCR-pMHC interactions had a large kon (>10
5
M1s1), pMHC potency correlated well with KD (Holler and
Kranz, 2003; Tian et al., 2007), whereas in studies where TCR-
pMHC interactions had a small kon (103 M1s1), pMHC
potency correlated well with koff (Krogsgaard et al., 2003). In
the present study, the kon values were intermediate (104
M1s1), providing an explanation as to why the full TCR-
pMHC confinement time model, but not the reduced models,
provided the best description of the data. In conclusion, the
confinement time model reconciles, and is supported by,
previously conflicting reports of the determinants of pMHC
potency.
Table 2. Analysis of Model Fitting to Data Subsets
pMHCs
Removeda
KD - koff
Correlation
Goodness-of-Fit Statisticsb F-Test for Model Comparisonc
KD koff CT MF CT+MF CT/KD CT/koff MF/koff CT+MF/CM CT+MF/MF
R2 R2 p R2 p R2 p R2 p R2 p p p p p p
0 0.74 0.72 1.70E-05 0.78 3.04E-06 0.83 3.94E-06 0.78 2.14E-05 0.89 2.12E-06 0.009 0.051 0.461 0.026 0.005
1 0.54 0.59 0.0005 0.65 0.0002 0.74 0.0001 0.70 0.0004 0.84 4.31E-05 0.014 0.043 0.166 0.019 0.006
2 0.39 0.47 0.0048 0.53 0.0021 0.66 0.0015 0.61 0.0038 0.80 0.0004 0.023 0.052 0.155 0.019 0.008
3 0.18 0.26 0.0621 0.24 0.0763 0.40 0.0577 0.34 0.0993 0.60 0.0235 0.131 0.108 0.213 0.054 0.031
4 1.2E-03 0.26 0.0738 0.21 0.1187 0.68 0.0034 0.31 0.1563 0.73 0.0062 0.005 0.003 0.249 0.224 0.005
5 1.0E-04 0.26 0.0876 0.14 0.2309 0.65 0.0085 0.59 0.0177 0.79 0.0041 0.011 0.005 0.012 0.048 0.024
6 4.4E-07 0.27 0.1050 0.21 0.1588 0.69 0.0095 0.32 0.2112 0.76 0.0150 0.011 0.008 0.279 0.205 0.010
7 1.2E-07 0.26 0.1313 0.15 0.2666 0.69 0.0157 0.58 0.0468 0.79 0.0191 0.016 0.010 0.031 0.156 0.053
8 1.5E-09 0.20 0.2229 0.20 0.2271 0.64 0.0463 0.29 0.3561 0.71 0.0833 0.035 0.035 0.414 0.332 0.044
9 6.3E-07 0.26 0.2004 0.20 0.2602 0.72 0.0400 0.31 0.3965 0.76 0.0994 0.033 0.028 0.424 0.486 0.052
a The first row corresponds to the entire data set of 17 pMHC variants and the last row, where nine pMHC are removed, corresponds to the subset of eight pMHC variants. Each subset represents the
set of pMHC variants that minimize the KD-koff correlation. See Results and Figure 4 for details on subset analysis. The quality of the fit for KD and koff models are shown in Figures 3A and 3B (entire
data set) and Figures 4C and 4D (subset of 13 pMHC variants).
b R2 and p values are calculated based on the quality of the fit and the number of free parameters for each model (see Experimental Procedures for details). Abbreviations: CT, confinement time
model; MF, molecular flexibility model; CT+MF, combined confinement and flexibility models. The quality of the fit for the CT, MF, and CT+MF models are shown in Figure 5 for the entire data set
(B, D, F) and for the subset of 13 pMHC variants (C, E, G).
c F-test provides a p value for the null hypothesis that the simpler model (with fewer parameters) is sufficient to explain the data. Simpler models are shown after the slash. Details are provided in the
Experimental Procedures.
Im
m
u
n
ity
T
C
R
-p
M
H
C
C
o
n
fi
n
e
m
e
n
t
T
im
e
a
n
d
T
C
e
ll
A
c
tiv
a
tio
n
Im
m
u
n
ity
3
2
,
1
6
3
–
1
7
4
,
F
e
b
ru
a
ry
2
6
,
2
0
1
0
ª
2
0
1
0
E
ls
e
v
ie
r
In
c
.
1
6
9
TCR
pMHC
kon
koff k
*
-
k+
0 0.02 0.04 0.06 0.08
0
100
200
300
400
500
R 2=0.73
Effective off−rate (s −1)
EC
50
0 0.1 0.2 0.3 0.4
0
100
200
300
400
500
R 2=0.68
Effective off−rate (k *
off
, s −1)
EC
50
0 0.02 0.04 0.06
0
200
400
600
800
R 2=0.89
Effective off−rate (s −1)
EC
50
0 0.5 1 1.5 2
0
200
400
600
800
R 2=0.83
Effective off−rate (k *
off
, s −1)
EC
50
0 0.5 1 1.5 2
0
200
400
600
800
R 2=0.78
Effective off−rate (s −1)
EC
50
0 0.1 0.2 0.3
0
100
200
300
400
500
R 2=0.31
Effective off−rate (s −1)
EC
50
Confinement time (CT) Molecular flexibility (MF) Combined CT + MF
E
nt
ire
 d
at
a 
se
t
S
ub
se
t o
f 1
3 
pM
H
C
B
A
D F
C E G
p=3.9E-06 p=2.1E-05 p=2.1E-06
p=0.0034 p=0.16 p=0.0062
Figure 5. Correlation of pMHC Potency with Effective Off Rates
(A) Model of TCR-pMHC confinement by rebinding. We used a mathematical model that accounted for a TCR-pMHC bound state (left), unbound but in physical
proximity state (center), and a state where TCR and pMHC havemoved apart (right). The rate of chemical dissociation is koff and the rate of association is k*on that
is a first order rate, in units of s1, that depends on themacroscopic on rate kon.When chemically dissociated (center), TCR-pMHCmaymove apart via diffusion or
transport with a first order rate k. We propose that the potency of pMHC is governed by the amount of time it is confined to the TCR. The effective off rate to go
from bound (left) to complete dissociation (right), given that potentially many rebinding events may take place, is given by k*off = (kkoff)/(k*on + k).
(B–G) The panels show fits of the confinement time (CT), molecular flexibility (MF), and the combined (CT+MF) models to the entire data set (B, D, F) or the subset
of 13 pMHC variants (C, E, G). The abscissa represents the effective off rate from each model. In the case of the confinement time model, it is (b2koff)/(kon + b2),
where b2 is a fitted parameter. In the case of the molecular flexibility model, the abscissa is koffexp(b2DCp), where b2 is a fitted parameter. See Experimental
Procedures for details on data fitting and representation of effective off rates.
Immunity
TCR-pMHC Confinement Time and T Cell ActivationTwo independent lines of evidence support a confinement
time model. First, there is evidence that interactions at the cell-
cell interface have longer half-lives than predicted from mea-
surements in solution (Grakoui et al., 1999; Tolentino et al.,
2008). Fluorescence recovery after photobleaching (FRAP)
experiments have demonstrated that the effective exchange
lifetime of a CD2-CD58 interaction in the membrane is 100 times
longer than the lifetime measured in solution (Tolentino et al.,
2008). Given that the intrinsic half life of a membrane-tethered170 Immunity 32, 163–174, February 26, 2010 ª2010 Elsevier Inc.interaction would be expected to be shorter because it is sub-
jected to mechanical forces (Bell, 1979), this suggests that
immediate rebinding after dissociation must be occurring. In
agreement with this observation, we find that the calculated
k*off of TCR-pMHC interaction (0.1 s1) is 10 times slower
than the koff measured in solution (1 s1). We note that several
factors, such as remodeling of cellular protrusions and thermal
fluctuations that alter the intermembrane separation, will exert
a mechanical force on the TCR-pMHC bond and therefore
Immunity
TCR-pMHC Confinement Time and T Cell Activationincrease the TCR-pMHC k*off. Therefore, the estimate of k*off is
probably a lower limit and the actual k*off may be larger. Direct
measurements of TCR-pMHC bond k*off at cell-cell interfaces
will inform on these aspects. A second line of evidence support-
ing the confinement time model is the finding by several groups
that increasing the mobility of pMHC on the cell surface inhibits
T cell antigen recognition (Luxembourg et al., 1998; Segura et al.,
2008; Wettstein et al., 1991). The confinement time model can
account for this hitherto unexplained finding because it predicts
that an increase in pMHC mobility will decrease rebinding and
therefore increase the effective koff.
It has been pointed out that the TCR-pMHC interaction, like all
interactions at a cell-cell interface, would be subjected to
mechanical forces, raising the possibility that the mechanical
strength of TCR-pMHC interaction might be an important deter-
minant of pMHC potency (van der Merwe, 2001). More recently it
has been proposed that a mechanical pulling force exerted by
pMHC binding could induce a conformational change in TCR-
CD3 complex that could contribute to TCR triggering (Choudhuri
and van derMerwe, 2007;Ma et al., 2008). It has been suggested
that the activation enthalpy of dissociation (DHzdiss) should corre-
late with mechanical strength, since, according to transition
state theory, it is a measure of the number of bonds that must
be broken during dissociation (Leckband, 2000), although this
remains to be proven. For this reason, we have analyzed transi-
tion state thermodynamics and determined the DHzdiss for 1G4
TCR interaction with the pMHC variants. However, we failed to
find a correlation of T cell activation with DHzdiss alone or in
combination with any other binding characteristic (not shown).
Because it remains unclear what, if any, solution binding param-
eter(s) correlate(s) precisely with mechanical strength, direct
measurements of the mechanical properties of TCR-pMHC
interactions (e.g., by atomic force microscopy) are probably
required to elucidate the role of mechanical forces in TCR trig-
gering and T cell activation.
The molecular flexibility model (Qi et al., 2006) proposes that
for some, conformationally flexible TCR-pMHC interactions,
immobilization in the membrane may increase the TCR-pMHC
bond lifetime compared to solution measurements. The model
predicts a simple relationship between the solution and mem-
brane lifetime that depends on DCp. We did not find substantial
effects of molecular flexibility for the data set in the present
study. We note, however, that structural studies indicate that
the 1G4 TCR undergoes only minor conformational changes
during binding to 9V-ESO-HLA-A2 (Chen et al., 2005). In addi-
tion, the DCp values, which range from 0.37 to 0.70 kcal/
mol K, are much smaller and less variable than those previously
reported by Krogsgaard et al. for the 2B4 TCR (Krogsgaard et al.,
2003; Qi et al., 2006). Therefore, the importance of molecular
flexibility (and DCp) may vary between different TCR-pMHC
systems and is hence an important topic for future investigation.
The observation that pMHC potency is determined by the
confinement time of TCR-pMHC has implications for models of
pMHC detection and discrimination. This finding implies that
the signaling state of the TCR persists during brief chemical
dissociation events. The consequence of this signal persistence
is that pMHC detection is based on a threshold in the confine-
ment time and therefore, discrimination is based on both kon
and the koff. Moreover, the ability of a T cell to discriminatebetween weak and strong agonist pMHC could be a result of
a slower kon rather than a faster koff. A mathematical model
that explicitly accounts for rebinding and signal persistence at
the TCR confirms these observations and shows that, in certain
parameter regimes, discrimination based on kon can be just as
sharp as koff (Dushek et al., 2009). In addition, requiring pMHC
with fast off rates to rebind TCRmultiple times before productive
signaling is initiated could act to reduce spurious signals gener-
ated by a high density of endogenous pMHC (fast off rates, small
on rates) that are unlikely to rebind TCR.
As noted in the Introduction, the mechanism of TCR triggering
remains controversial. Three main types of models have been
proposed invoking conformation change, aggregation, or segre-
gation of the TCR-CD3 complex upon pMHC engagement, and
these mechanisms are not mutually exclusive (reviewed in
Choudhuri and van der Merwe, 2007). Although our study does
not directly address mechanisms of TCR triggering, our finding
that T cell activation depends on the confinement time places
important constraints on the details of these models. The key
constraint is that the TCR signaling mechanism is not disrupted
or interrupted when the TCR dissociates briefly between rebind-
ing events. It follows that conformational change in the TCR-CD3
complex would either need to be stable between rebinding or
there would need to be an early rapid modification that is stable
between rebinding events but will be readily reversed after com-
plete dissociation. In short, there is a requirement for some
memory mechanism at the level of the TCR after chemical disso-
ciation. To our knowledge no existing models of conformational
change explicitly propose a memory mechanism.
The kinetic-segregation (K-S) model of TCR triggering posits
that pMHC binding leads to confinement of the TCR-CD3
complex within close-contact zones deficient in tyrosine phos-
phatases and/or enriched in Src tyrosine kinases (Davis and
van der Merwe, 1996). The confinement time model would not
allow lateral TCR-CD3 diffusion out of close contact zones
during the brief periods between rebinding events, so it is entirely
compatible with the K-S model without any modifications. The
essence of aggregation models is the induced proximity of
TCR-CD3 complexes after pMHC engagement. In these models
termination of signaling requires diffusion of TCR-CD3 com-
plexes, and the confinement time model requires that there is
no diffusion between rebinding, so it follows that aggregation
models are also compatible with the importance of confinement
time. It is noteworthy that either the aggregation or K-S mecha-
nism could provide the ‘‘memory’’ necessary for conformational
change models to be compatible with the confinement time
model. Thus any model that combined the aggregation or segre-
gation with conformational change would be compatible with
confinement time model.
Protein interactions in the membrane environment are com-
plex and dynamic and differ significantly from interactions in
solution. Our model aims to capture the most important aspects
of this complexity but it has to be mentioned that, although
improved over simple models, correlation of T cell activation
with confinement time calculated from the solution properties
of the TCR-pMHC is not perfect. One possible explanation for
this is that these solution measurements do not correlate
perfectly with the actual binding properties of membrane-asso-
ciated molecules. Direct measurements of 2D binding kineticsImmunity 32, 163–174, February 26, 2010 ª2010 Elsevier Inc. 171
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this point fully. Another possible explanation for this imperfect
correlation is that conformational changes in the TCR are
required for TCR triggering (Beddoe et al., 2009) and pMHC vari-
ants differ in their propensity to induce the required conforma-
tional change.
It is likely that coreceptor (CD8) binding to pMHC will increase
the TCR-pMHC confinement time. If the contribution of corecep-
tors is similar for all pMHC variants, coreceptor binding may not
affect the relationship between TCR-pMHC binding parameters
and T cell activation. Our finding that confinement time corre-
lated with pMHC potency in a system in which CD8 engagement
occurs is consistent with this. Point mutations in HLA-A2 that
disrupt CD8 binding strongly abrogate recognition by 1G4
T cells (Chen et al., 2005), rendering them unresponsive to low-
affinity pMHC variants (KD > 20 mM). Unfortunately this precluded
an analysis of the contribution of CD8 to pMHC potency in this
system because most pMHC variants have a low affinity.
In conclusion, we have demonstrated the importance of TCR-
pMHC kon in determining the outcome of T cell antigen recog-
nition. We show that the dependence on kon can best be
accounted for by a confinement time model, in which there is
repeated rebinding after TCR-pMHC chemical dissociation and
the outcome of TCR engagement is dependent on the length
of time until complete dissociation. Our model can account for
previous, apparently contradictory, findings and provide an
explanation for the hitherto unexplained dependence of TCR
triggering on pMHC mobility. Although this confinement time
model is compatible with existing aggregation or segregation
models of TCR triggering, it requires modification of conforma-
tional change models to include a mechanism for ‘‘memory’’
between rebinding events.EXPERIMENTAL PROCEDURES
Surface Plasmon Resonance
Protein subunits of 1G4 TCR and HLA-A2 were expressed in E. coli, purified,
and refolded in vitro, as described in Supplemental Experimental Procedures.
Binding properties of 1G4 TCR interaction with ESO-9V pMHC variants were
analyzed by SPR on a BIAcore 3000 (GE Healthcare Life Sciences, Little Chal-
font Bucks, UK). Binding affinity was analyzed by measuring equilibrium
binding of graded concentrations of 1G4 TCR to immobilized pMHC. Kinetic
data were obtained by injecting 1G4 TCR over the immobilized pMHC and
analysis of the dissociation phase curve fitting in BIAevaluation software.
Binding thermodynamics was analyzed by measuring affinity and kinetics at
the range of temperatures, calculating binding energy (DG and DzGdiss), and
fitting data to the van’t Hoff equation. Details of binding analysis by SPR can
be found in Supplemental Experimental Procedures.
Assays for 1G4 CTL Activation by pMHC Variants
1G4 CTLs were stimulated by graded levels of plate-immobilized pMHC for
4 hr and levels of released IFN-g was measured from the cell supernatant by
ELISA. Cytotoxic response of 1G4 CTLs to various ESO-9V APLs was
analyzed by incubating 1G4CTLswith 51Cr loaded T2 cells pulsedwith various
ESO-9V APLs for 4 hr and measuring levels of released 51Cr from lysed T2
cells. Further details can be found in the Supplemental Experimental Proce-
dures.
Model of TCR-pMHC Confinement Time
We capture the effect of TCR-pMHC confinement via the theory of diffusion-
limited reactions on membranes (Lauffenburger and Linderman, 1993; Shoup
and Szabo, 1982). The model can be represented as follows:172 Immunity 32, 163–174, February 26, 2010 ª2010 Elsevier Inc.R+P4
k+
k
F4
kon
koff
C;where TCR (R) and pMHC (P) first form an encounter complex (F), where the
two molecules are within physical proximity but chemically dissociated, and
subsequently they may bind to form a TCR-pMHC complex (C). The diffu-
sion-limited on rate (in units of mm2/s) is given by k+ = 2pD/ln(b/s), where D
is the diffusion coefficient, b is the mean distance between TCR, and s is the
reaction radius (roughly the size of a TCR). The remaining microscopic rates
(koff, k*on, k), on the scale of a single TCR-pMHC, are all first order (in units
of s1) and are related to the experimentally measured macroscopic rates
(see below). Assuming that TCR-pMHC are initially bound, we can calculate
the mean time that the molecules will spend in each state before moving apart,
Tf =
1
k
;
Tc =
kon + k
k
1
koff
;
where Tf and Tc are the time spent in the unbound (F) and bound (C) states,
respectively, integrated across multiple rebinding events. The TCR-pMHC
bond lifetime (1/koff) is much larger than 1/k (see below) and therefore Tc > >
Tf, indicating that TCR-pMHC spend negligible time within physical proximity
but chemically unbound. The total TCR-pMHC confinement time is then T = Tc,
whose reciprocal gives an effective off rate describing the rate at which TCR-
pMHCmove apart, k*off = 1/T (see Results). We note that amacroscopicmodel
of pMHC confinement time to a cluster of TCR predicts that the confinement
time is governed by KD (Dushek and Coombs, 2008).
The rates in the model (k*on, k-) are first order because we are considering
reactions between proteins in physical proximity and it is reasonable to
assume that they are proportional to macroscopic parameters that are mea-
sured in experiments. The solution on rate (kon) in units of M
1s1 can be con-
verted to a 2Dmembrane on rate (in units of mm2/s) by a confinement length (L)
with a factor of 1015/(NAL), where NA is Avogadro’s number. The 2Dmembrane
on rate can be related to the intrinsic on rate (k*on in units of s
1) by the effective
local TCR concentration (1 TCR in an area A = ps2, where s is the previously
defined reaction radius). We can therefore relate the experimentally measured
solution on rate to the intrinsic on rate by a multiplicative factor, k*on = skon
where s = 1015/(NALA). Assuming that diffusion is the primary determinant of
the relative TCR-pMHC mobility, the rate at which TCR-pMHC move apart
when unbound (k) is directly related to the diffusion-limited membrane on
rate; k = k+/A. By using reasonable parameters (D = 0.05 mm
2/s, s = 0.005 mm,
b = 0.05 mm, and a TCR concentration of 100 mm2), we calculated that k+z
0.1 mm2/s and therefore 1/k is several orders of magnitude smaller than 1/koff,
indicating that the TCR-pMHC confinement time is dominated by the time in
the bound state (Tc > > Tf). The exact relationship between the intrinsic and
macroscopic rates is not important for our conclusions.Statistical Analysis and Model Fitting
The equations used to fit the fivemodels we have focused on (Figure 4B) are as
follows:
y=b0 +b1 KD;
y=b0 +b1 koff;
y=b0 +b1 koff=ðkon +b2Þ; Confinement Time ðCTÞ
y=b0 +b1 koffexpðb2DCpÞ; Molecular FlexiblityðMFÞ
y=b0 +b1 koffexpðb3DCpÞ
ðkon +b2Þ; Combined CT+MF;
where y is the measure of pMHC potency (i.e., y = EC50) and bi are free param-
eters. All data fitting was performed with the Matlab function lsqcurvefit. Re-
ported R2 statistics and associated p values (calculated by an F-test) are
computedwith standardmethods. Themodels we investigate contain different
numbers of free parameters and therefore it is not possible to directly compare
the R2 statistic because additional parameters will always lead to larger R2
Immunity
TCR-pMHC Confinement Time and T Cell Activationvalues. To determine the significance of increased R2 values in models with
more parameters, we compute an F-score (Motulsky and Christopoulos,
2004):
F =
ðSSR1  SSR2Þ=ðp2  p1Þ
SSR2=ðn p2Þ
where SSR is the sum squared residuals, p is the number of free or fitted
parameters, and n is the number of data points. The subscript 1 refers to the
simpler model with fewer parameters. A p value is computed based on the
F-score from the F-distribution with (p2 – p1, n – p2) degrees of freedom and
is used to test the null hypothesis that the simpler model (with fewer parame-
ters) is sufficient to explain the data (see Table 2).
Representation of Effective Off Rates
In order to explore the importance of TCR-pMHC confinement time, we per-
formed data fitting with the effective off rate (y = b0 + b’1 k*off). By using the defi-
nition of k*off, we fitted the following equation: y = b0 + b1 koff/(kon + b2). In this
equation, b1 = b’1 k/s and b2 = k/s. In order to visualize the quality of the fits,
we have plotted results in terms of the effective off rate (see Figure 5), k*off = b2
koff/(kon + b2), where b2 is determined from the fit (see above). The effective off
rate for the molecular flexibility model is simply koff exp(b2 DCp), where b2 is
a fitted parameter.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and two tables can be found with this article online at doi:
10.1016/j.immuni.2009.11.013.
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